ArticleCureus2026
Reverse Left Ventricular Remodeling in a Patient With Concurrent Wild-Type Transthyretin Cardiac Amyloidosis and Heart Failure With Reduced Ejection Fraction: The Role of Conventional Heart Failure Therapy.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Wild-type transthyretin amyloid (ATTRwt) amyloidosis is a systemic, progressive disease that often affects older adults and is characterized by ATTRwt deposition in multiple organs and tissues. When the heart is involved, this deposition leads to cardiac amyloidosis (CA), which can result in life-threatening heart failure (HF) and arrhythmias. In general, as left ventricular (LV) wall thickening increases because of ATTRwt deposition, the LV cavity decreases in size. Additionally, as the disease progresses, the myocardial ATTR burden increases, and the LV ejection fraction (LVEF) decreases. Thus, at ATTRwt-CA diagnosis, the most common LV characteristics are a slightly reduced LV cavity and preserved or mildly reduced LVEF. We report the case of an 83-year-old man with HF with reduced EF (HFrEF) and ATTRwt-CA who had an LVEF of 22% and a dilated LV cavity with an end-diastolic diameter (EDD) of 58.0 mm and end-diastolic volume index (EDVI) of 86 mL/m
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.